MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Royalty Pharma plc EPS Ratio 2011-2026 | RPRX
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Royalty Pharma plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.79 | 1.92 | 2.54 | 0.1 | 1.49 | 1.32 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.54 | 0.1 | 1.53 |
Quarterly EPS Ratio Royalty Pharma plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.67 | 0.07 | 0.55 | 1.22 | 0.23 | 0.01 | 0.16 | 0.51 | 0.76 | - | 0.32 | 0.7 | 0.12 | - | 0.24 | 1.08 | 0.18 | - | 0.79 | 0.09 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.22 | 0.01 | 0.453 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
Assembly Biosciences
ASMB
|
-0.55 | $ 28.46 | - | $ 319 M |  USA |
 |
Ascendis Pharma A/S
ASND
|
-8.28 | $ 221.88 | - | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.29 | - | $ 7.92 B |  Australia |
 |
Autolus Therapeutics plc
AUTL
|
-0.86 | $ 1.37 | - | $ 350 M |  Britain |
 |
Axsome Therapeutics
AXSM
|
-3.68 | $ 156.92 | - | $ 7.81 B | USA |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.82 | $ 54.13 | - | $ 10.4 B | USA |
 |
Benitec Biopharma
BNTC
|
-0.21 | $ 10.98 | - | $ 452 M | USA |
 |
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | USA |
 |
Burford Capital Limited
BUR
|
75.3 | $ 7.7 | - | $ 1.31 B | Britain |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-3.51 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | Canada |
 |
Avenue Therapeutics
ATXI
|
-15.8 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | USA |
 |
Compugen Ltd.
CGEN
|
0.38 | $ 2.09 | - | $ 195 M |  Israel |
 |
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | Israel |
 |
AbCellera Biologics
ABCL
|
-0.49 | $ 3.4 | - | $ 1.02 B | Canada |
 |
Atreca
BCEL
|
-2.52 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Cara Therapeutics
CARA
|
-2.19 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-1.89 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-2.08 | - | -74.18 % | $ 955 K | USA |
 |
Coherus BioSciences
CHRS
|
1.43 | $ 1.52 | - | $ 178 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-1.42 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-2.29 | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | Germany |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-5.9 | $ 8.6 | - | $ 115 M | USA |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
Curis
CRIS
|
-6.88 | $ 0.77 | - | $ 4.86 M | USA |
 |
Cellectis S.A.
CLLS
|
-2.55 | $ 3.34 | - | $ 116 M | France |
 |
Arbutus Biopharma Corporation
ABUS
|
-0.44 | $ 4.24 | - | $ 704 M | Canada |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | USA |